Second Positive DSMB Safety Nod Keeps Phase 3 Alzheimer's Trial on Track
ANVS sits 30% above its 52-week low of $0.616.
Summary
An independent DSMB recommended that the Phase 3 DUET-AD trial of buntanetap in early Alzheimer's continue without modification after reviewing safety data through September 22, 2026, from 861 patients. It is the second consecutive positive review, following the 6-month feedback announced in February 2026. Management says detailed safety outcomes will be reported in March alongside the 6-month symptomatic results. The trial timeline holds: last patient last visit for the 6-month period expected December 31, 2026, database lock February 8, 2027, and 6-month topline results in March 2027. The readout is the binary event for a company this size, and the safety clearance at scale removes one overhang ahead of it. The company ended Q3 with $2.8 million of cash and a going-concern warning, funded by the $21.0 million November offering, so the March data is what the balance sheet is now riding on.
At the time of this announcement, ANVS was trading at $0.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32M. The 52-week trading range was $0.62 to $5.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.